The rapid clinical and scientific progress of immuno-oncology (IO) since the approval of the first immune checkpoint inhibitors has changed the spectrum of patient care forever. Recognizing the milestones of the past and considering the obstacles ahead for the field, the Society for Immunotherapy of Cancer (SITC) capitalized on this critical inflection point to convene a diverse group of experts in cancer immunotherapy, from academia, the pharmaceutical and biotechnology industries, patient advocacy, and the regulatory community, to provide a roadmap to the next wave of novel immuno-therapies for cancer patients.
Within this JITC special series, leading experts in the field will outline the current state of the field, elevate the most pressing challenges, and propose the most promising opportunities for high clinical impact in the scientific, clinical, and regulatory arenas of cancer immunotherapy.
“The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cancer (SITC)” will serve as the leading resource to chart the path from discovery to oncology patient care.
Check the collection throughout 2024 for new publications.